This clinical trial is focused on studying the effects of a medication called ozanimod in patients with relapsing-remitting multiple sclerosis (RRMS). Multiple sclerosis is a disease where the immune system mistakenly attacks the protective covering of nerves, which can lead to symptoms like fatigue, difficulty walking, and problems with vision. The purpose of this study is to evaluate how ozanimod can help limit the progression of brain damage over a period of two years in people with this condition.

Participants in the study will receive ozanimod, which is taken orally, meaning it is swallowed in pill form. The study will observe changes in the brain, such as overall brain shrinkage and specific areas like the gray matter, white matter, thalamus, and cortex. These observations will help researchers understand how the medication affects the brain and whether it can slow down the damage caused by the disease.

Throughout the study, researchers will also look at how ozanimod impacts other aspects of the participants’ lives, including their cognitive abilities, levels of fatigue, mood, and overall quality of life. This comprehensive approach aims to provide a better understanding of how the medication can improve the daily lives of those living with relapsing-remitting multiple sclerosis.